PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

A recalled sickle cell drug is drawing new scrutiny from attorneys who say it may have done more harm than good, possibly ...

At recent prices, the yield you receive from Pfizer is more than four times the amount you'd receive from the average dividend payer in the S&P 500. If it can't maintain its payout-raising streak, ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

When the FDA unexpectedly uploaded around 200 drug rejection letters this week, the regulator provided an in-depth view | ...

The Food and Drug Administration (FDA) granted full approval on Thursday to Moderna’s COVID-19 vaccine for children, making it the first COVID shot for kids aged 6 months to 11 years old that is ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two COVID-19 vaccines ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two COVID-19 vaccines ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and showing good tolerability.

An FDA advisory panel will meet July 18 to consider a supplemental new drug application for the antipsychotic brexpiprazole, ...

Pfizer PFE has committed significant resources for the development of treatments in the fields of oncology, internal medicine, immunology, inflammation and vaccines. Over the past decade, Pfizer has ...